DaVita(US:DVA) ZACKS·2025-12-23 00:01Company Performance - DaVita HealthCare (DVA) closed at $116.51, with a daily increase of +1.14%, outperforming the S&P 500's gain of 0.64% [1] - Over the past month, DVA shares have decreased by 4.2%, underperforming the Medical sector's increase of 2.25% and the S&P 500's increase of 3% [1] Earnings Projections - The upcoming EPS for DaVita HealthCare is projected at $3.34, indicating a significant increase of 49.11% compared to the same quarter last year [2] - Revenue is expected to reach $3.53 billion, reflecting a growth of 6.99% year-over-year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $10.52 per share, representing an increase of 8.68% from the previous year [3] - Revenue for the fiscal year is estimated at $13.55 billion, indicating a growth of 5.75% compared to the prior year [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for DaVita HealthCare should be monitored, as they often reflect short-term business trends [4] - Positive estimate revisions are interpreted as favorable indicators for the business outlook [4] Zacks Rank and Valuation - DaVita HealthCare currently holds a Zacks Rank of 3 (Hold), with the EPS estimate remaining unchanged over the last 30 days [6] - The company is trading at a Forward P/E ratio of 10.95, which is below the industry average of 19.65 [7] - DaVita has a PEG ratio of 0.87, compared to the industry average PEG ratio of 1.96 [7] Industry Context - The Medical - Outpatient and Home Healthcare industry ranks in the top 22% of all industries, with a current Zacks Industry Rank of 53 [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]